AI blood test could spot lung cancer return earlier

NCT ID NCT07291921

Recruiting now Knowledge-focused Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether advanced blood tests and artificial intelligence can help detect lung cancer recurrence earlier and without invasive procedures. About 100 adults who had surgery for stage IB-IIIA lung cancer and received standard chemo-immunotherapy before surgery will provide blood samples over time. The goal is to build a better monitoring system to catch any remaining or returning cancer sooner.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm Neoplasm, Residual non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY LUNG NEOPLASMS MINIMAL RESIDUAL DISEASE NEOADJUVANT THERAPY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

Contact Phone: •••-•••-•••• Email: •••••@•••••